Brief: Jacobio Pharmaceuticals Group Receives China CDE Investigational New Drug- Clearance For KRAS G12C Inhibitor
28/05/2021 02:41
May 28 (Reuters) - Jacobio Pharmaceuticals Group Co Ltd
1167.HK :
* JACOBIO RECEIVES CHINA CDE INVESTIGATIONAL NEW DRUG-
CLEARANCE
FOR KRAS G12C INHIBITOR
Source text for Eikon: ID:nHKSc7kbsT
Further company coverage: 1167.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan